Edward Nash
Stock Analyst at Canaccord Genuity
(3.90)
# 783
Out of 5,182 analysts
78
Total ratings
52.11%
Success rate
10.69%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $47 → $56 | $40.29 | +38.99% | 11 | Apr 14, 2026 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $8 | $1.51 | +429.80% | 4 | Apr 6, 2026 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 → $5 | $0.97 | +413.51% | 3 | Apr 1, 2026 | |
| CORT Corcept Therapeutics | Maintains: Buy | $100 → $110 | $46.34 | +137.38% | 13 | Mar 26, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $89 → $130 | $90.92 | +42.98% | 2 | Mar 24, 2026 | |
| PLRX Pliant Therapeutics | Maintains: Hold | $4 → $3 | $1.29 | +132.56% | 3 | Mar 13, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $62 | $42.46 | +46.02% | 1 | Feb 19, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.43 | +928.81% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $527.11 | +11.36% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $35.53 | +201.15% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $6.44 | +334.78% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.59 | +257.78% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 | $34.38 | +80.34% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.37 | +404.45% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.83 | -47.78% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.75 | +23,744.22% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.19 | +410.54% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $25.06 | +227.21% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $18.04 | +166.08% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.48 | +11,761.31% | 1 | Nov 8, 2017 |
Travere Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $47 → $56
Current: $40.29
Upside: +38.99%
Cardiol Therapeutics
Apr 6, 2026
Maintains: Buy
Price Target: $8
Current: $1.51
Upside: +429.80%
Rani Therapeutics Holdings
Apr 1, 2026
Maintains: Buy
Price Target: $9 → $5
Current: $0.97
Upside: +413.51%
Corcept Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $100 → $110
Current: $46.34
Upside: +137.38%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $89 → $130
Current: $90.92
Upside: +42.98%
Pliant Therapeutics
Mar 13, 2026
Maintains: Hold
Price Target: $4 → $3
Current: $1.29
Upside: +132.56%
Kiniksa Pharmaceuticals International,
Feb 19, 2026
Initiates: Buy
Price Target: $62
Current: $42.46
Upside: +46.02%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.43
Upside: +928.81%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $527.11
Upside: +11.36%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $35.53
Upside: +201.15%
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $6.44
Upside: +334.78%
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $5.59
Upside: +257.78%
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $34.38
Upside: +80.34%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.37
Upside: +404.45%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.83
Upside: -47.78%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.75
Upside: +23,744.22%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.19
Upside: +410.54%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $25.06
Upside: +227.21%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $18.04
Upside: +166.08%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.48
Upside: +11,761.31%